Eli Lilly: 1 Big Reason for UK Gateway Lab Reconsideration
Reports suggest pharmaceutical giant Eli Lilly is reconsidering its major UK Gateway Lab investment. Learn why the company’s future plans in Britain are now uncertain.
pharmaceutical
Read More
3 wins for Regeneron: Phase 3 trial success vs allergies
Regeneron’s itepekimab antibody treatment posts 3 wins in Phase 3 trials, showing significant improvement against both cat allergies and seasonal pollen allergies.